Join Oncopeptides for a live virtual program for a newly approved Multiple Myeloma medication

Please join Oncopeptides on Wednesday, April 8th, for a live virtual
program featuring Dr. Christopher Maisel who will discuss a
newly-approved therapy for adult patients with multiple myeloma who
have received at least four prior lines of therapy and are triple-class
refractory.

Introducing PEPAXTO: The first anticancer peptide-drug conjugate for
multiple myeloma patients who have received ≥4 prior lines and are
triple-class refractory

Presented by: Christopher Maisel, MD Hematologist/Oncologist Texas
Oncology P.A.

Thursday, April 08, 2021 06:00 PM CDT

Virtual Program Dial In: +19292056099,,94753585816#

Webinar Link,
https://thecmgroup.zoom.us/j/94753585816?pwd=UXpJTW1XVGgzTE5DdmR2Mm1DOVVpQT09

To register for this program, please contact your Oncopeptides
representative: CMG Coordinator (848) 448-4473 or
oncopeptidessp@thecmgroup.com

Please RSVP at least 3 days in advance of the program

I hope you will be able to join us for this educational peer-to-peer
discussion. Please do not hesitate to contact me with any questions.

Thank you,

Jeanne

Jeanne P. Marriott

Oncology Area Business Manager - Arkansas/TN

Email: Jeanne.marriott@oncopeptides.com

Cell: 501.837.6672

www.pepaxto.com 

www.oncopeptides.com